Print | Share | Contact Us | Search:

NPS Pharmaceuticals is a global biopharmaceutical company that is pioneering and delivering therapies to transform the lives of patients with rare diseases worldwide.

The company’s lead product, Gattex®(U.S.)/Revestive®(EU) 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use is approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS is also developing Natpara® (rhPTH[1-84]) for the treatment of adult hypoparathyroidism and expects to submit its Biologic License Application (BLA) to the FDA in the second half of 2013.

NPS complements its internal clinical programs with a valuable royalty-generating portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, and Ortho-McNeil.

  Board of Directors
  Contact Us